# Jounce Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/jounce-therapeutics

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: www.jouncetx.com
- Total disclosed funding: $88M
- Latest round: Series B (Apr 23, 2015)
- Investors on record: 9

## About

Based in the US, Jounce Therapeutics, Inc. specializes in developing innovative immune-oncology therapies designed to enhance patient outcomes in cancer treatment.Jounce Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, US. The company focuses on immune-oncology and has undergone significant strategic development, including a successful IPO in January 2017 raising USD 101.84 mn. As of January 2021, Jounce raised USD 56.25 mn in a Private Placement/Follow on. The company has executed a total of 5 deals, with the most recent deal occurring on March 9, 2021. Rich Murray serves as the CEO of the firm.Jounce Therapeutics, Inc. specializes in the development of immune-oncology therapies specifically targeting cancer treatment. Its proprietary product pipeline includes therapies designed to enhance the body's immune response against cancerous cells, contributing to advancements in oncology and patient care.In the most recent fiscal year 2022, Jounce Therapeutics generated revenue of USD 82.00 mn, with an EBITDA of USD -49.25 mn.Jounce Therapeutics plans to utilize the funds raised from its latest Private Placement in January 2021 to support ongoing studies and clinical trials for its product portfolio. The company aims to expand its offerings in the immune-oncology sector, targeting new markets in North America and Europe. Future product launches and advancements in therapeutic solutions are anticipated as part of their growth strategy.

## Funding rounds

- Series B, Apr 23, 2015, $56M — Wellington Management, Nextech, Omega Funds, Foresite Capital, Redmile Group, Casdin Capital, Cormorant Asset Management, Pharmstandard International S.A.
- Series A, Feb 14, 2013, $32M — Third Rock Ventures

## Investors

- Third Rock Ventures (https://capitalatlas.ai/funds/third-rock-ventures) — Series A
- Wellington Management (https://capitalatlas.ai/funds/wellington-management) — Series B
- Nextech (https://capitalatlas.ai/funds/nextech) — Series B
- Omega Funds (https://capitalatlas.ai/funds/omega-funds) — Series B
- Foresite Capital (https://capitalatlas.ai/funds/foresite-capital) — Series B
- Redmile Group (https://capitalatlas.ai/funds/redmile-group) — Series B
- Casdin Capital (https://capitalatlas.ai/funds/casdin-capital) — Series B
- Cormorant Asset Management (https://capitalatlas.ai/funds/cormorant-asset-management) — Series B
- Pharmstandard International S.A. — Series B